Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 data of Sotagliflozin (LX4211) for Type 1 Diabetes due 2H 2016

Source Link:: http://www.lexpharma.com/news/press-releases/2402-sanofi-and-lexicon-pharmaceuticals-to-collaborate-on-sotagliflozin-an-investigational-new-oral-medicine-for-people-with-diabetes.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

LXRX

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The developmental medicine sotagliflozin (LX4211) is currently being studied in two pivotal Phase 3 trials in type 1 diabetes, which are expected to report top-line results during the second half of 2016.

http://www.lexpharma...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 09, 2016

Occurred Source:

http://www.lexicon-genetics.com/news/press-releases/2442-lexicon-reports-positive-top-line-results-in-pivotal-phase-3-study-for-sotagliflozin-in-patients-with-type-1-diabetes.html

Related Projects

Assessing the market potential of Lexicon's sotagliflozin (LX4211) after positive Phase 3 results in their inTANDEM 1 & 2 trials were published. LXRX Executed On: Dec 08, 2017 at 11:00 AM EST

Related Keywords Phase 3 Data, Sotagliflozin, Type 1 Diabetes, 2h 2016, Lx4211